Brainstorm Cell Therapeutics (STU:GHD) Other Financing: €0.39 Mil (TTM As of Mar. 2026)


STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
28 GF Score
Price €2.98
! 3 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Other Financing?

Brainstorm Cell Therapeutics STU:GHD 28 Other Financing is €0.39 Mil as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Brainstorm Cell Therapeutics's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

Brainstorm Cell Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.39 Mil.

Brainstorm Cell Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Other Financing Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 1.67

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 0.39 0.00 0.00 0.00
STU:GHD
28GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.39 Mil mean?
Brainstorm Cell Therapeutics (STU:GHD) has a Other Financing of €0.39 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Other Financing too high?
Brainstorm Cell Therapeutics' current Other Financing is €0.39 Mil. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Other Financing compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' Other Financing of €0.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Other Financing is €0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current Other Financing of €0.39 Mil. The current Other Financing is €0.39 Mil. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current Other Financing is €0.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for STU:GHD

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price